Welcome to our dedicated page for BriaCell Therapeutics Warrant news (Ticker: BCTXW), a resource for investors and traders seeking the latest updates and insights on BriaCell Therapeutics Warrant stock.
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company based in Los Angeles. They specialize in developing targeted and safe immunotherapy approaches for cancer management, with a current focus on breast cancer. The company has seen success with their patented 'BriaVax' vaccine in FDA Phase I studies, showing promising results. BriaCell is gearing up for a Phase I/II study to broaden the application of their vaccine technology. They are also working on Bria-OTS, personalized immunotherapy for advanced-stage breast cancer.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announces the addition of Suzanne Ostrand-Rosenberg, Ph.D. to its Scientific Advisory Board. Dr. Ostrand-Rosenberg boasts over 40 years of experience in cancer immunology and has contributed significantly to the understanding of the immune response to cancer. Her notable research includes work on CD4+ T-helper lymphocytes and myeloid-derived suppressor cells. The collaboration aims to enhance BriaCell's pipeline of immunotherapies, particularly for advanced breast cancer.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has appointed Dr. Jane Gross to its Board of Directors. With over 30 years of biotech experience, Dr. Gross has held significant roles at various companies, emphasizing her expertise in cancer therapeutics. The Board hopes to leverage her insights to advance BriaCell's immunotherapy pipeline. Additionally, the company granted stock options to Dr. Gross and its Scientific Advisory Board. BriaCell also announced a contract with North Equities Corp. for marketing and investor engagement purposes, costing CAD$105,000.
BriaCell Therapeutics Corp. (BCTX, BCTXW) recognizes October as Breast Cancer Awareness Month, highlighting the ongoing need for effective breast cancer treatments. The company, with $57 million cash as of July 31, 2021, continues its targeted immunotherapy program, achieving a notable 12-month overall survival benefit in trials and resolving a severe tumor in a patient. Additionally, BriaCell has initiated a securities buyback program to enhance shareholder value. The company emphasizes its commitment to treating patients beyond mere statistics.
BriaCell Therapeutics Corp. (BCTX, BCTXW) announces significant advancements in its immunotherapy for advanced breast cancer. In a recent interview, CEO Dr. Bill Williams highlighted a partnership with ImaginAb to assess the safety and efficacy of their treatments. The board has expanded to include corporate finance expert Marc Lustig, and the company plans to utilize over $55 million in excess capital for share repurchases. Dr. Williams emphasized the need to align the company’s valuation with its clinical progress, addressing concerns regarding its current market valuation.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has received approval from the TSX Venture Exchange for a normal course issuer bid (the “Buyback”). This allows the company to repurchase up to 1,341,515 common shares and 411,962 warrants over the next 12 months, starting September 28, 2021. This Buyback, managed by Independent Trading Group Inc., represents 10% of the public float as of September 21, 2021. The company assures that this initiative will not disrupt its growth plans in cancer immunotherapy and ongoing clinical trials.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) will present at the Benzinga Healthcare Small Cap Conference on September 29-30, 2021. Dr. Bill Williams, President and CEO, is scheduled to speak at 1:15 PM ET on September 29. The event will be held virtually, and investors can register for a free spectator pass. BriaCell focuses on immunotherapies for advanced breast cancer, aiming to provide targeted treatment approaches. For more details, visit briacell.com.
BriaCell Therapeutics Corp. (BCTX, BCTXW) has authorized a repurchase program for up to 1,341,515 common shares and 411,962 warrants, representing 10% of the public float. With a cash balance of US$57 million as of July 31, 2021, the buyback is expected to enhance shareholder value. The Company is advancing its cancer immunotherapy pipeline, with key studies planned for 2022. The buyback will not interfere with BriaCell's growth initiatives in cancer treatments. Independent Trading Group will manage the repurchase program, which is subject to regulatory approvals.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announced the appointment of Marc Lustig to its Board of Directors, effective September 1, 2021. Lustig, a significant shareholder with 10% ownership through L5 Capital Inc., brings extensive experience in corporate finance and pharmaceuticals. He aims to enhance the company's capital markets strategy. The Board also approved a grant of 100,000 options to Lustig at C$7.24 per share, vesting immediately, with proceeds intended for donation to the Cedars Cancer Foundation.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) will participate in the H.C. Wainwright 23rd Annual Global Investment Conference held virtually from September 13-15, 2021. Dr. William Williams, President & CEO, will outline the company's business during the presentation scheduled for September 13 at 7:00 A.M. (ET). Investors can access the presentation online through the provided link, with archived access for 90 days. BriaCell focuses on targeted immunotherapies for advanced breast cancer and is committed to innovative cancer management approaches.
BriaCell Therapeutics has entered into a multi-year, non-exclusive license agreement with ImaginAb to utilize its advanced CD8 ImmunoPET imaging technology for analyzing tumor-attacking CD8 T cells in breast cancer patients. This partnership supplements BriaCell's ongoing Phase I/IIa study and aims to enhance the assessment of safety and efficacy for its immunotherapy treatments. The collaboration is expected to accelerate drug development and improve patient care, with continued clinical doses and technical support from ImaginAb.
FAQ
What is the current stock price of BriaCell Therapeutics Warrant (BCTXW)?
What is BriaCell Therapeutics Corp focused on?
What is the significance of BriaVax vaccine?
What upcoming clinical trial is BriaCell preparing for?
What is Bria-OTS and its purpose?
Where is BriaCell Therapeutics Corp headquartered?
How can I contact BriaCell for more information?
Who is the Media Relations contact for BriaCell?
How can investors get in touch with BriaCell?
What type of clinical trial is BriaCell conducting for breast cancer?
What is BriaCell's outlook on expanding their technology?
